We are live on ! Find out more
CPRX

Catalyst Pharmaceutical
CPRX

Delisted

CPRX was delisted on the 14th of July, 2026.

Back to rankings

88 hedge funds and large institutions have $314M invested in Catalyst Pharmaceutical in 2019 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 25 increasing their positions, 27 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

232% more capital invested

Capital invested by funds: $94.3M → $314M (+$219M)

15% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 13

12.03% more ownership

Funds ownership: 47.83% → 59.85% (+12%)

2% more funds holding

Funds holding: 86 → 88 (+2)

7% less repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 27

43% less call options, than puts

Call options by funds: $683K | Put options by funds: $1.19M

Holders
88
Holders Change
+2
Holders Change %
+2.33%
% of All Funds
1.9%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.06%
New
15
Increased
25
Reduced
27
Closed
13
Calls
$683K
Puts
$1.19M
Net Calls
-$505K
Net Calls Change
-$424K

Top Buyers

1
CCM
Consonance Capital Management
New York
+$24.9M
2
OM
Opaleye Management
Massachusetts
+$5.36M
3
MP
Mangrove Partners
Connecticut
+$3.2M
4
KCM
Kennedy Capital Management
Missouri
+$2.94M
5
HRCM
Hawk Ridge Capital Management
California
+$1.93M

Top Sellers

1
Morgan Stanley
Morgan Stanley
New York
-$2.76M
2
BC
Broadfin Capital
New York
-$1.21M
3
PAM
Panagora Asset Management
Massachusetts
-$920K
4
DMK
David M. Knott
-$302K
5
IG
ING Group
Netherlands
-$271K
Name Holding Trade Value Shares
Change 		Change in
Stake
GWS
76
Glassman Wealth Services
Virginia
$63K – – –
USAA
77
United Services Automobile Association
Texas
$63K – – –
ARTA
78
A.R.T. Advisors
New York
$59K -$228K -77,657 -87%
HSA
79
HBK Sorce Advisory
Pennsylvania
$57K – – –
ProShare Advisors
80
ProShare Advisors
Maryland
$53K +$958 +326 +3%
WIC
81
Whitegate Investment Counselors
New Hampshire
$51K – – –
AIP
82
Ameritas Investment Partners
Nebraska
$46K – – –
Bank of Montreal
83
Bank of Montreal
Ontario, Canada
$26K -$4K -1,361 -21%
MAM
84
Meeder Asset Management
Ohio
$9K -$95.6K -32,534 -95%
QI
85
QS Investors
New York
$7K – – –
VRM
86
Vectors Research Management
New York
$5K – – –
Carson Wealth (CWM LLC)
87
Carson Wealth (CWM LLC)
Nebraska
$5K +$853 +290 +58%
RFC
88
Regions Financial Corp
Alabama
$5K +$2.94K +1,000 New
Two Sigma Investments
89
Two Sigma Investments
New York
– -$271K -141,004 Closed
IG
90
ING Group
Netherlands
– -$271K -140,911 Closed
Susquehanna International Group
91
Susquehanna International Group
Pennsylvania
– -$140K -47,578 Closed
Squarepoint
92
Squarepoint
New York
– -$87K -45,147 Closed
Connor, Clark & Lunn Investment Management (CC&L)
93
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
– -$70K -36,700 Closed
UBS Group
94
UBS Group
Switzerland
– -$69K -35,811 Closed
Invesco
95
Invesco
Georgia
– -$49K -25,652 Closed
CHAM
96
Clear Harbor Asset Management
Connecticut
– -$33K -16,950 Closed
Group One Trading
97
Group One Trading
Illinois
– -$49.3K -16,764 Closed
PP
98
Paloma Partners
Connecticut
– -$30K -15,740 Closed
TRCT
99
Tower Research Capital (TRC)
New York
– -$21K -10,769 Closed
AGM
100
Alpine Global Management
New York
– -$20K -10,374 Closed
1 2 3
4
5

CPRX Hedge Fund Activity: Q1 2019 in Review

88 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q1 2019, worth a combined $314M — up 232% from $94.3M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new CPRX positions and 13 closed out — a net gain of 2 holders — while 25 added to existing stakes and 27 trimmed.

The largest buyer was Consonance Capital Management, adding an estimated $24.9M. The largest seller was Morgan Stanley, cutting an estimated $2.76M.

  • 88 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q1 2019, up from 86 in Q4 2018.
  • Funds reported $314M of Catalyst Pharmaceutical stock for Q1 2019, up 232% quarter-over-quarter.
  • 15 funds opened new Catalyst Pharmaceutical positions in Q1 2019 and 13 closed out, a net change of +2 holders.
  • The largest Catalyst Pharmaceutical buyer in Q1 2019 was Consonance Capital Management, an estimated $24.9M added.
  • The largest Catalyst Pharmaceutical seller in Q1 2019 was Morgan Stanley, an estimated $2.76M sold.

Based on aggregated 13F filings for Q1 2019.